EUCTR2014-000057-37-NL进行中（未招募）1 期
A B2-agonist as a CFTR activator in CF - ABBA study
niversity Medical Centre Utrecht0 个研究点开始时间: 2014年2月12日最近更新:
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •-CFTR genotype compound/A455E or compound/R117H
- •-CFTR measurement available in intestinal biopsies
- •-Males and females, aged 18 years or older on the date of informed consent
- •-Signed informed consent form (ICF)
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 10
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range
排除标准
- •-Severe acute exacerbation or pulmonary infection (needing intravenous treatment and/or systemic corticosteroids)
- •-Known cardiovascular medical history like cardiac failure, arrhythmias, ischemic cardiac disease, long QT interval syndrome and hypertension
- •-Known hyperthyroidism, thyrotoxicosis, galactose intolerance, lactase deficiency or glucose-galactose malabsorption
- •-HBA1C > 45 mmol/mol
- •-Use of B2 agonist one week prior to the start of the study (V1)
- •-Use of: heart glycoside, high dose sympathomimetics, theophylline, thiazide diuretics or non-selective beta-blockers
- •-Pregnancy or breastfeeding
- •-Participation in another drug-investigating clinical study at the start or within 1 month prior to the start
- •-Inability to follow instructions of the investigator
研究者
相似试验
已完成
2 期
A B2-agonist as a CFTR activator in CF10083624Cystic FibrosisMucoviscidosisNL-OMON40957niversitair Medisch Centrum Utrecht10
尚未招募
不适用
A B2-agonist as a CFTR activator in CF Part IICystic FibrosisNL-OMON24538niversity Medical Center Utrecht20
进行中（未招募）
1 期
A B2-agonist as a CFTR activator in CF - Part 2Cystic fibrosisEUCTR2015-001317-28-NLMC Utrecht
已完成
不适用
A B2-agonist as a CFTR activator in CFCFTR residual function, Salbutamol, CFTR activation, personalized medicineNL-OMON21450MCU Utrecht, Prof. dr. C.K. van der Ent10
已完成
2 期
A B2-agonist as a CFTR activator in CF - Part 210083624Cystic FibrosisMucoviscidosisNL-OMON43663niversitair Medisch Centrum Utrecht14